Melissa Benoit

Understanding Your Mutation

Medications Currently Available

Ivacaftor (Kalydeco):

Ivacaftor has Health Canada approval for individuals with CF who have one of the following CF mutations G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D or G970R

Ivacaftor (Kalydeco) is funded if you have private drug insurance and also through the Ontario Drug Benefits (ODB) program.   To access the ODB, you must apply for coverage through the Trillium Drug Program and the clinic must apply for special access to ivacaftor. Please contact the clinic for more details about the Trillium Drug Program and access to ivacaftor.

Ivacaftor has Health Canada approval for individuals 18 years of age and older with CF who have the R117H mutation.   Private insurance providers may cover ivacaftor for people with R117H.  Public coverage for Kalydeco is not yet available for people with the R117H mutation.

 

Combination of Ivacaftor and Lumacaftor (Orkambi):

Orkambi was granted Health Canada approval on January 26, 2016 for individuals with CF over the age of 12 years who have 2 copies of the delta F508 (also known as F508del) mutation.

Private insurance providers may cover the cost of ivacaftor/lumacaftor (Orkambi) for people with F508del/F508del.  Public coverage for Orkambi is not available.

Please come to clinic to hear more about Orkambi and how it would fit into your treatment routine. 


In Trials Only

VX-661 and Ivacaftor:

Individuals with the following combination of mutations delta F508/delta F508, or G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, G970R, R117H on one allele and delta F508 on the other allele. 

 


To learn more about the different classes of mutations, click here.